Cencora Shares Drop on Revenue Outlook Cut

Dow Jones05-06

By Katherine Hamilton

Cencora shares fell after the company cut its revenue outlook following lower-than-expected quarterly revenue.

The stock slid 18% to $252.03 on Wednesday, at one point hitting a 52-week low. Shares have lost about a quarter of their value this year.

The drug distributor said it now expects full-year revenue to increase 4% to 6%, down from its previous range of 7% to 9% growth. Cencora is now expecting lower revenue growth in its U.S. healthcare solutions segment, Chief Financial Officer Jim Cleary said.

Revenue in the most-recently ended quarter rose 3.8% to $78.36 billion, below the $81.09 billion analysts were projecting.

Adjusted earnings per share were $4.75, missing the $4.82 that Wall Street was forecasting, according to FactSet.

Cencora executives told analysts they are seeing slower-than-expected growth from GLP-1s, which contributed to the company's lower guidance.

The Inflation Reduction Act also is continuing to reduce the Wholesale Acquisition Cost for certain drugs covered by Medicare, which Cencora said resulted in a $2 billion dent in sales and a 3% headwind to U.S. revenue growth in the quarter.

Cencora also lost a grocery customer and an oncology customer during the quarter, it said. There were faster-than-anticipated brand conversions at a large mail-order customers that contributed to reduced revenue growth.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 06, 2026 10:56 ET (14:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633340581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633340581","market":"fut","top_or_hot":-1,"title":"Cencora Shares Drop on Revenue Outlook Cut","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Cencora shares fell after the company cut its revenue outlook following lower-than-expected quarterly revenue. \n</p>\n<p>\n  The stock slid 18% to $252.03 on Wednesday, at one point hitting a 52-week low. Shares have lost about a quarter of their value this year. \n</p>\n<p>\n  The drug distributor said it now expects full-year revenue to increase 4% to 6%, down from its previous range of 7% to 9% growth. Cencora is now expecting lower revenue growth in its U.S. healthcare solutions segment, Chief Financial Officer Jim Cleary said. \n</p>\n<p>\n  Revenue in the most-recently ended quarter rose 3.8% to $78.36 billion, below the $81.09 billion analysts were projecting. \n</p>\n<p>\n  Adjusted earnings per share were $4.75, missing the $4.82 that Wall Street was forecasting, according to FactSet. \n</p>\n<p>\n  Cencora executives told analysts they are seeing slower-than-expected growth from GLP-1s, which contributed to the company's lower guidance. \n</p>\n<p>\n  The Inflation Reduction Act also is continuing to reduce the Wholesale Acquisition Cost for certain drugs covered by Medicare, which Cencora said resulted in a $2 billion dent in sales and a 3% headwind to U.S. revenue growth in the quarter. \n</p>\n<p>\n  Cencora also lost a grocery customer and an oncology customer during the quarter, it said. There were faster-than-anticipated brand conversions at a large mail-order customers that contributed to reduced revenue growth. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2026 10:56 ET (14:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cencora Shares Drop on Revenue Outlook Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCencora Shares Drop on Revenue Outlook Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-06 22:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Cencora shares fell after the company cut its revenue outlook following lower-than-expected quarterly revenue. \n</p>\n<p>\n  The stock slid 18% to $252.03 on Wednesday, at one point hitting a 52-week low. Shares have lost about a quarter of their value this year. \n</p>\n<p>\n  The drug distributor said it now expects full-year revenue to increase 4% to 6%, down from its previous range of 7% to 9% growth. Cencora is now expecting lower revenue growth in its U.S. healthcare solutions segment, Chief Financial Officer Jim Cleary said. \n</p>\n<p>\n  Revenue in the most-recently ended quarter rose 3.8% to $78.36 billion, below the $81.09 billion analysts were projecting. \n</p>\n<p>\n  Adjusted earnings per share were $4.75, missing the $4.82 that Wall Street was forecasting, according to FactSet. \n</p>\n<p>\n  Cencora executives told analysts they are seeing slower-than-expected growth from GLP-1s, which contributed to the company's lower guidance. \n</p>\n<p>\n  The Inflation Reduction Act also is continuing to reduce the Wholesale Acquisition Cost for certain drugs covered by Medicare, which Cencora said resulted in a $2 billion dent in sales and a 3% headwind to U.S. revenue growth in the quarter. \n</p>\n<p>\n  Cencora also lost a grocery customer and an oncology customer during the quarter, it said. There were faster-than-anticipated brand conversions at a large mail-order customers that contributed to reduced revenue growth. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2026 10:56 ET (14:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1261432733.SGD","symbol_name":"Fidelity World A-ACC-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633340581","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633340581","pubTimestamp":1778079360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cencora shares fell after the company cut its revenue outlook following lower-than-expected quarterly revenue.The stock slid 18% to $252.03 on Wednesday, at one point hitting a 52-week low. Shares have lost about a quarter of their value this year.The drug distributor said it now expects full-year revenue to increase 4% to 6%, down from its previous range of 7% to 9% growth. Cencora is now expecting lower revenue growth in its U.S. healthcare solutions segment, Chief Financial Officer Jim Cleary said.Revenue in the most-recently ended quarter rose 3.8% to $78.36 billion, below the $81.09 billion analysts were projecting.Adjusted earnings per share were $4.75, missing the $4.82 that Wall Street was forecasting, according to FactSet.Cencora executives told analysts they are seeing slower-than-expected growth from GLP-1s, which contributed to the company's lower guidance.Cencora also lost a grocery customer and an oncology customer during the quarter, it said. There were faster-than-antic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1261432733.SGD":"Fidelity World A-ACC-SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4588":"碎股","COR":"CENCORA","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4084":"特种房地产投资信托","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","BK4529":"IDC概念","BK4175":"保健护理产品经销商"},"translate_title":"Cencora股价因收入前景下调而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COR":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Cencora shares fell after the company cut its revenue outlook following lower-than-expected quarterly revenue. \n\n\n  The stock slid 18% to $252.03 on Wednesday, at one point hitting a 52-week low. Shares have lost about a quarter of their value this year. \n\n\n  The drug distributor said it now expects full-year revenue to increase 4% to 6%, down from its previous range of 7% to 9% growth. Cencora is now expecting lower revenue growth in its U.S. healthcare solutions segment, Chief Financial Officer Jim Cleary said. \n\n\n  Revenue in the most-recently ended quarter rose 3.8% to $78.36 billion, below the $81.09 billion analysts were projecting. \n\n\n  Adjusted earnings per share were $4.75, missing the $4.82 that Wall Street was forecasting, according to FactSet. \n\n\n  Cencora executives told analysts they are seeing slower-than-expected growth from GLP-1s, which contributed to the company's lower guidance. \n\n\n  The Inflation Reduction Act also is continuing to reduce the Wholesale Acquisition Cost for certain drugs covered by Medicare, which Cencora said resulted in a $2 billion dent in sales and a 3% headwind to U.S. revenue growth in the quarter. \n\n\n  Cencora also lost a grocery customer and an oncology customer during the quarter, it said. There were faster-than-anticipated brand conversions at a large mail-order customers that contributed to reduced revenue growth. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2026 10:56 ET (14:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633340581","isCrawlerRequest":true}